Vericel (NASDAQ:VCEL) Trading Down 4.1% – Should You Sell?

by · The Cerbat Gem

Vericel Corporation (NASDAQ:VCEL – Get Free Report)’s share price fell 4.1% on Wednesday . The company traded as low as $40.73 and last traded at $40.7750. 203,580 shares changed hands during trading, a decline of 64% from the average session volume of 568,149 shares. The stock had previously closed at $42.54.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. Truist Financial reaffirmed a “buy” rating and set a $50.00 price target (up previously from $41.00) on shares of Vericel in a research report on Monday, November 10th. Zacks Research downgraded shares of Vericel from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 12th. Wall Street Zen raised Vericel from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Canaccord Genuity Group lowered their target price on Vericel from $61.00 to $58.00 and set a “buy” rating for the company in a research report on Friday, August 1st. Finally, BTIG Research cut shares of Vericel from a “buy” rating to a “neutral” rating in a research report on Wednesday, September 17th. Four investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $58.75.

Get Our Latest Stock Report on Vericel

Vericel Stock Performance

The firm has a market capitalization of $2.07 billion, a PE ratio of 339.78 and a beta of 1.41. The stock’s 50 day simple moving average is $35.31 and its two-hundred day simple moving average is $37.71.

Vericel (NASDAQ:VCEL – Get Free Report) last issued its quarterly earnings results on Thursday, November 6th. The biotechnology company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.02) by $0.12. Vericel had a return on equity of 2.47% and a net margin of 2.85%.The firm had revenue of $67.50 million for the quarter, compared to analysts’ expectations of $64.57 million. During the same quarter in the previous year, the firm posted ($0.02) EPS. The firm’s revenue for the quarter was up 16.6% on a year-over-year basis. Vericel has set its FY 2025 guidance at EPS. Equities research analysts expect that Vericel Corporation will post 0.14 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Vericel

Hedge funds have recently bought and sold shares of the business. Huntington National Bank grew its position in shares of Vericel by 51.3% during the third quarter. Huntington National Bank now owns 805 shares of the biotechnology company’s stock worth $25,000 after buying an additional 273 shares in the last quarter. Ameritas Advisory Services LLC acquired a new position in Vericel during the 2nd quarter valued at approximately $30,000. Abich Financial Wealth Management LLC bought a new position in shares of Vericel during the third quarter worth about $31,000. CWM LLC raised its stake in shares of Vericel by 101.3% in the 2nd quarter. CWM LLC now owns 1,379 shares of the biotechnology company’s stock worth $59,000 after buying an additional 694 shares in the last quarter. Finally, AlphaQuest LLC acquired a new stake in shares of Vericel in the second quarter valued at $60,000.

About Vericel

(Get Free Report)

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.

See Also